Institute of Mental Health

Belgrade 11000

3 studies enrolling now · 17 studies all time

What they study most

Alzheimer's Disease Psychosis, Bipolar 1 Depression, Bipolar Disorder, Cognitive Dysfunction, Depression, Depressive Disorder, Major, Depressive Episode, Irritability Associated With Autism Spectrum Disorder, Lewy Body Dementia Psychosis, Major Depressive Disorder With Mixed Features, Negative Symptoms, Partial Epilepsy

Studies at this site

• ACP-204 in Adults With Alzheimer's Disease Psychosis — Recruiting now
• Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — Recruiting now
• ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study — Enrolling by invitation
• Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis — Enrolling by invitation
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia — Completed
• Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder — Stopped early
• Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder — Completed
• A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures — Completed
• Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures — Completed
• A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression — Completed
• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age — Stopped early
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) — Completed
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia — Stopped early
• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder — Completed
• Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose — Completed
• PEARL Schizophrenia Maintenance — Completed
• Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia — Completed